MigraineSalHeadNCT03727672
Salivary Inflammatory Markers in Tension Type Headache and Migraine
An observational study of Migraine and Tension-Type Headache, run by National and Kapodistrian University of Athens at 1 site in Greece.
Trial summary
Data role of salivary inflammatory markers in migraine and Tension Type headache (TTH) are lacking. Τhe investigators studied whether headache attacks are associated with changes in C reactive protein (CRP), Interleukin -1β and Interleukin -6 in saliva in patients with Tension Type Headache and Migraine and age… Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Migraine, Tension-Type Headache
- How many people
- 90 participants
- Where
- 1 siteGreece
- Study dates
- 1 Jan 2016to 30 Dec 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Subjects of both genders, aged from 18 to 60 years old, with primary headaches TTH and migraine, according to the International Classification of Headache Disorders, 3rd edition (beta version), were enrolled from the outpatient headache clinic of the first Neurological Hospital of University of Athens between January to March 2016. Fifteen healthy control subjects aged matched were recruited mainly from hospital staff and patients' relatives
Who may be able to join
- aged from 18 to 60 years old
- Tension type Headache (TTH) and migraine, fulfilling the criteria International Classification of Headache Disorders, 3rd edition (beta version)
Who cannot join
- abnormal plasma CRP, Interleukin-1β and Interleukin-6 levels (>10 mg/L)
- smoking cigarettes > 1 pack/day;
- current pregnancy, lactation, or hormonal contraceptive use
- alcohol or substance abuse
- drug use such as anticoagulants, statins, or hormonal drugs
- anti-inflammatory therapy
Show all 9Show fewer
- other primary or secondary headaches
- major psychiatric disease
- oral health problems.
Trial locations and contacts
1 site in 1 country.
Greece1 site
Eginition Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Athens, 11528
About this study
Official title: Salivary Inflammatory Markers (Interleukin -1β, Interleukin -6, C- Reactive Protein) in Tension Type Headache and Migraine
Data role of salivary inflammatory markers in migraine and Tension Type headache (TTH) are lacking. Τhe investigators studied whether headache attacks are associated with changes in C reactive protein (CRP), Interleukin -1β and Interleukin -6 in saliva in patients with Tension Type Headache and Migraine and age matched healthy controls . Τhe investigators, also investigated whether these markers could be influenced by comorbidities such as depression and anxiety.
Read the detailed description
Sixty subjects of both genders, aged from 18 to 60 years old, with primary headaches TTH and migraine, according to the International Classification of Headache Disorders, 3rd edition (beta version), were enrolled from the outpatient headache clinic of University Hospital of Athens between January to March 2016. 30 healthy control subjects aged matched were recruited mainly from hospital staff and patients' relatives.
Initially, the participants completed the Hamilton Anxiety (HAM-A), Scale Beck Depression Inventory (BDI). All patients had to keep a headache diary during the four-week run-in period. All headache suffers were instructed to collected salivary headache-free baseline samples at the time of study screening when they had been free of headache for at least 48 hours (time point A). All headache suffers collected additional samples during moderate/severe headache (time point B), and at self-defined resolution phase 24 hours of their headache attack (time point C). Healthy control subjects were instructed to collected samples at the time of study screening (time point D). Every week, until four weeks and one month after the end of the study, participants were contacted, in order to ensure the compliance and the appropriate use of the technique. One year later longitudinal data would also be obtain.
Saliva Sample Collection Detailed instructions for the correct collection of saliva samples were given to all participants. Such instructions include avoiding eating a major meal and teeth brushing 60 minutes prior to sample collection. Also consumption of high sugar and caffeine content foods as well as high acidity foods have to be excluded before saliva sample collection. Mouth rinse with water in order to remove any food residue and saliva sample collection at least 10 minutes after mouth rinse was recommended. Unstimulated whole saliva that pooled on the mouth floor were collected from patients and healthy volunteers in high quality polypropylene vials by the passive drool technique. Finally, all samples were stored in a plastic container at 2-4 ° C until analysis. Saliva was collected from the participants, at 8.00 a.m. in the morning in order to rule out any confounding factor caused by circadian rhythm.
Sample Analysis Morning samples were kept in the refrigerator at 4°C and at the end of the day were brought to the laboratory where they were centrifuged 3000 rpm at 4°C and the supernatant was aliquoted in to polypropylene Cryogenic vials. Vials were frozen in -80°C until analyzed. Saliva transferrin levels were measured by competitive immunoassay kits and Interleukin-6, Interleukin-1β and CRP levels were measured by sandwich ELISA kits. Transferrin levels were used as a screening tool for the presence of blood in saliva samples and samples with transferrin values greater than 1 mg/dl were considered as candidates for exclusion in other salivary assays. Cortisol assay has a sensitivity of < 0.007 μg/ml and an inter-assay coefficient of variation of < 11% while these characteristics are 0.07 pg/ml and 8 for Interleukin-6, 0.37 pg/ml and 7 for Interleukin-1β, 10 pg/ml and 11.2 for CRP as well as 0.08 mg/dl and 7.2 for transferrin respectively.
- Conditions
- Migraine, Tension-Type Headache
- Keywords
- Primary headaches, CRP, Interleukin1β, Interleukin6, markers
- Medical subject headings
- Migraine Disorders, Tension-Type Headache
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Tension type headache patients | 30 subjects of both genders, aged from 18 to 60 years old, with primary headaches (TTH) , according to the International Classification of Headache Disorders, 3rd edition (beta version) , were enrolled from the outpatient headache clinic of the first Neurological Hospital of University of Athens between January to March 2016. | |
| Migraine patients | 30 subjects of both genders, aged from 18 to 60 years old, with migraine, according to the International Classification of Headache Disorders, 3rd edition (beta version) , were enrolled from the outpatient headache clinic of the first Neurological Hospital of University of Athens between January to March 2016. | |
| age matched controls | 30 healthy control subjects aged matched were recruited mainly from hospital staff and patients' relatives |
What is being measured
The primary outcome is the main question the study is designed to answer.
migraine/Tension type Headache and C reactive protein
establish whether attacks of migraine and Tension type Headache are associated with changes in the concentration of C reactive protein
Measured: 2 years
migraine/Tension type Headache and Interleukin -1β
establish whether attacks of migraine and Tension type Headache are associated with changes in the concentration of Interleukin-1β
Measured: 2 years
migraine/Tension type Headache and Interleukin-6 levels
establish whether attacks of migraine and Tension type Headache are associated with changes in the concentration of Interleukin-6 levels
Measured: 2 years
Secondary outcomes (5)
C reactive protein concentrations
C reactive protein concentrations as assessed using sandwich ELISA kits
Measured: 2 years
Interleukin-1β concentrations
Interleukin-1β concentrations as assessed using sandwich ELISA kits
Measured: 2 years
Interleukin-6 levels concentrations
Interleukin-6 levels concentrations as assessed using sandwich ELISA kits
Measured: 2,5 years
Anxiety
Anxiety as assessed using the Hamilton Anxiety (HAM-A)
Measured: 2,5 years
Depression
Depression as assessed using the Beck Depression Inventory (BDI)
Measured: 2,5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Nov 2018
- Study start1 Jan 2016
- Primary completion30 Dec 2020 (estimated)
- Study completion30 Dec 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for MigraineStudies of the same condition, open and under way.
- More trials run by National and Kapodistrian University of AthensThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National and Kapodistrian University of Athens
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Anastasia Bougea, National and Kapodistrian University of Athens
- Investigators
- ANASTASIA BOUGEA, PHD, Principal investigator, National and Kapodistrian University of Athens
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03727672
- Sponsor's protocol ID
- 638/5.11.2015
- Acronym
- SalHead
- Status last verified
- Sep 2020
- First submitted
- 23 Oct 2018
- Last updated
- 10 Sep 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: database
Publications
Sjogren E, Leanderson P, Kristenson M, Ernerudh J. Interleukin-6 levels in relation to psychosocial factors: studies on serum, saliva, and in vitro production by blood mononuclear cells. Brain Behav Immun. 2006 May;20(3):270-8. doi: 10.1016/j.bbi.2005.08.001. Epub 2005 Sep 23.
PubMed 16183246
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Salivary Inflammatory Markers (Interleukin -1β, Interleukin -6, C- Reactive Protein) in Tension Type Headache and Migraine
- ClinicalTrials.gov ID
- NCT03727672
- Acronym / sponsor ID
- SalHead / 638/5.11.2015
- Conditions
- Migraine, Tension-Type Headache
- Keywords
- Primary headaches, CRP, Interleukin1β, Interleukin6, markers
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- National and Kapodistrian University of AthensUniversity, hospital or other
- Study start
- 1 Jan 2016 (actual)
- Primary completion
- 30 Dec 2020 (estimated)
- Study completion
- 30 Dec 2020 (estimated)
- First posted
- 1 Nov 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Data role of salivary inflammatory markers in migraine and Tension Type headache (TTH) are lacking. Τhe investigators studied whether headache attacks are associated with changes in C reactive protein (CRP), Interleukin -1β and Interleukin -6 in saliva in patients with Tension Type Headache and Migraine and age matched healthy controls . Τhe investigators, also investigated whether these markers could be influenced by comorbidities such as depression and anxiety.
Detailed description
Sixty subjects of both genders, aged from 18 to 60 years old, with primary headaches TTH and migraine, according to the International Classification of Headache Disorders, 3rd edition (beta version), were enrolled from the outpatient headache clinic of University Hospital of Athens between January to March 2016. 30 healthy control subjects aged matched were recruited mainly from hospital staff and patients' relatives.
Initially, the participants completed the Hamilton Anxiety (HAM-A), Scale Beck Depression Inventory (BDI). All patients had to keep a headache diary during the four-week run-in period. All headache suffers were instructed to collected salivary headache-free baseline samples at the time of study screening when they had been free of headache for at least 48 hours (time point A). All headache suffers collected additional samples during moderate/severe headache (time point B), and at self-defined resolution phase 24 hours of their headache attack (time point C). Healthy control subjects were instructed to collected samples at the time of study screening (time point D). Every week, until four weeks and one month after the end of the study, participants were contacted, in order to ensure the compliance and the appropriate use of the technique. One year later longitudinal data would also be obtain.
Saliva Sample Collection Detailed instructions for the correct collection of saliva samples were given to all participants. Such instructions include avoiding eating a major meal and teeth brushing 60 minutes prior to sample collection. Also consumption of high sugar and caffeine content foods as well as high acidity foods have to be excluded before saliva sample collection. Mouth rinse with water in order to remove any food residue and saliva sample collection at least 10 minutes after mouth rinse was recommended. Unstimulated whole saliva that pooled on the mouth floor were collected from patients and healthy volunteers in high quality polypropylene vials by the passive drool technique. Finally, all samples were stored in a plastic container at 2-4 ° C until analysis. Saliva was collected from the participants, at 8.00 a.m. in the morning in order to rule out any confounding factor caused by circadian rhythm.
Sample Analysis Morning samples were kept in the refrigerator at 4°C and at the end of the day were brought to the laboratory where they were centrifuged 3000 rpm at 4°C and the supernatant was aliquoted in to polypropylene Cryogenic vials. Vials were frozen in -80°C until analyzed. Saliva transferrin levels were measured by competitive immunoassay kits and Interleukin-6, Interleukin-1β and CRP levels were measured by sandwich ELISA kits. Transferrin levels were used as a screening tool for the presence of blood in saliva samples and samples with transferrin values greater than 1 mg/dl were considered as candidates for exclusion in other salivary assays. Cortisol assay has a sensitivity of < 0.007 μg/ml and an inter-assay coefficient of variation of < 11% while these characteristics are 0.07 pg/ml and 8 for Interleukin-6, 0.37 pg/ml and 7 for Interleukin-1β, 10 pg/ml and 11.2 for CRP as well as 0.08 mg/dl and 7.2 for transferrin respectively.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Tension type headache patients | – | –30 subjects of both genders, aged from 18 to 60 years old, with primary headaches (TTH) , according to the International Classification of Headache Disorders, 3rd edition (beta version) , were enrolled from the outpatient headache clinic of the first Neurological Hospital of University of Athens between January to March 2016. |
| Migraine patients | – | –30 subjects of both genders, aged from 18 to 60 years old, with migraine, according to the International Classification of Headache Disorders, 3rd edition (beta version) , were enrolled from the outpatient headache clinic of the first Neurological Hospital of University of Athens between January to March 2016. |
| age matched controls | – | –30 healthy control subjects aged matched were recruited mainly from hospital staff and patients' relatives |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Subjects of both genders, aged from 18 to 60 years old, with primary headaches TTH and migraine, according to the International Classification of Headache Disorders, 3rd edition (beta version), were enrolled from the outpatient headache clinic of the first Neurological Hospital of University of Athens between January to March 2016. Fifteen healthy control subjects aged matched were recruited mainly from hospital staff and patients' relatives
Key inclusion criteria (2 listed)
- aged from 18 to 60 years old
- Tension type Headache (TTH) and migraine, fulfilling the criteria International Classification of Headache Disorders, 3rd edition (beta version)
Key exclusion criteria (9 listed)
- abnormal plasma CRP, Interleukin-1β and Interleukin-6 levels (>10 mg/L)
- smoking cigarettes > 1 pack/day;
- current pregnancy, lactation, or hormonal contraceptive use
- alcohol or substance abuse
- drug use such as anticoagulants, statins, or hormonal drugs
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
migraine/Tension type Headache and C reactive protein
Time frame: 2 years
establish whether attacks of migraine and Tension type Headache are associated with changes in the concentration of C reactive protein
migraine/Tension type Headache and Interleukin -1β
Time frame: 2 years
establish whether attacks of migraine and Tension type Headache are associated with changes in the concentration of Interleukin-1β
migraine/Tension type Headache and Interleukin-6 levels
Time frame: 2 years
establish whether attacks of migraine and Tension type Headache are associated with changes in the concentration of Interleukin-6 levels
5 secondary outcomes
C reactive protein concentrations
Time frame: 2 years
Interleukin-1β concentrations
Time frame: 2 years
Interleukin-6 levels concentrations
Time frame: 2,5 years
Anxiety
Time frame: 2,5 years
Depression
Time frame: 2,5 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2020.
- Results publication: PubMed 16183246Sjogren E, Leanderson P, Kristenson M, Ernerudh J. Interleukin-6 levels in relation to psychosocial factors: studies on serum, saliva, and in vitro production by blood mononuclear cells. Brain Behav Immun. 2006 May;20(3):270-8. doi: 10.1016/j.bbi.2005.08.001. Epub 2005 Sep 23.
- Individual participant dataSharing planned: Undecided. database
Related trials for Migraine
RecruitingObservational study
Study of the Glymphatic System in Migraine
Migraine
Active, not recruiting
Clinical and Neurophysiological Effects of tDCS to Visual and Motor Cortex in Migraine
Migraine
Active, not recruiting
App-Based Migraine Treatment: The Health enSuite Study
Migraine, Migraine With Aura
Not yet recruiting
A Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare Professionals
Migraine Disorders
Recruiting
Marine Lipids Ease Painful TMD
Temporomandibular Disorder (TMD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
ANASTASIA BOUGEA, PHD principal investigator
National and Kapodistrian University of Athens
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Migraine and Tension-Type Headache, run by National and Kapodistrian University of Athens at 1 site in Greece.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 10 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
migraine/Tension type Headache and C reactive protein (time frame: 2 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03727672, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2020.